Fig. 7
From: AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
AXL inhibitor with osimertinib inhibited growth of AXL-high tumors in vivo. a PC-9 cell-line-derived xenograft (CDX) tumors were treated with vehicle (control), NPS1034 50 mg/kg, osimertinib 5 mg/kg, or NPS1034 50 mg/kg plus osimertinib 5 mg/kg (n = 6 each). Tumor volumes were measured over time from the start of treatment and the results are shown (mean ± SEM). b PC-9 CDX tumors were treated with osimertinib (5 mg/kg) for 8 days followed by the continuous administration of 5 mg/kg osimertinib or in combination with 50 mg/kg NPS1034 (n = 7 each) administered. The results of tumor volume are plotted (mean ± SEM). c The indicated cells and patient-derived xenograft (PDX) tumors (TM00784) were lysed and the indicated proteins were detected by western blotting. d PDX tumors (TM00784) were untreated (control), treated with 50 mg/kg NPS1034, 5 mg/kg osimertinib, or a combination of 50 mg/kg NPS1034 and 5 mg/kg osimertinib (n = 4 each). The results of tumor volume are plotted (mean ± SEM). e PDX tumors (TM00784) were treated with 5 mg/kg osimertinib for 7 days followed by continuous administration of 5 mg/kg osimertinib or in combination with 50 mg/kg NPS1034 (n = 4 each). The results of tumor volume are plotted (mean ± SE)
